Keywords: cell, genesys, shares, crash, after, deaths, gvax

Cell Genesys shares crash 70% after deaths in GVAX trial

Article | 01 September 2008

Print This

Cell Genesys has terminated VITAL-2, the second of two Phase III trials of its GVAX immunotherapy for prostate cancer, due ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in